Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

J. B. Chemicals & Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. The company's API product portfolio includes diclofenac sodium, diethylamine, acid, and potassium; nifedipine, atenolol, and cilnidipine; and ciprofloxacin, cetirizine, and meclizine HCI. It also provides dosage forms, such as tablets, lozenges, injectables, gels, creams, ointments, liquid herbal syrups, cold rubs, eye drops, troches, and capsules; and soft-centered, powder, medicated, and herbal lozenges, as well as various pharmaceutical dosage forms. In addition, it offers a range of contrast media products, including x-ray, magnetic resonance imaging (MRI), and ultrasound scanners; and contract manufacturing services. The company provides its products in gastroenterology, anti-infectives, wound care, neonatology and pediatrics, gynaecology, dental, vitamins and minerals, hypertension, diabetes, nephrology, respiratory, pain-analgesic, dermatology, antivirals, lozenges, and contrast media and radio diagnostic therapeutic areas. J. B. Chemicals & Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for JBCHEPHARM
Revenue projections for JBCHEPHARM

J. B. Chemicals & Pharmaceuticals Limited's revenues are expected to fall below last year's, and this forecast tends to raise concerns among investors. A revenue drop can negatively impact the company's profitability, making investors more cautious about their positions due to the risks of declining financial performance.

Financial Ratios:

currentRatio 0.000000
forwardPE 33.465603
debtToEquity 1.075000
earningsGrowth 0.216000
revenueGrowth 0.105000
grossMargins 0.670510
operatingMargins 0.235240
trailingEps 47.410000
forwardEps 59.771820

Positive earnings and revenue growth for JBCHEPHARM suggest that the company is positioned for business expansion. The company's strong financial performance indicates sustained growth, as increasing sales and profits fuel its future success.
JBCHEPHARM's positive gross and operating margins indicate that the company is performing profitably. These margins reflect efficient cost control and revenue generation, signaling a strong financial foundation for continued success.
With a forward EPS greater than its trailing EPS, JBCHEPHARM is expected to see higher profitability this year. The forecasted increase in earnings reflects optimism about the company's financial growth and potential for improved performance over the prior year.

Price projections:

Price projections for JBCHEPHARM
Price projections for JBCHEPHARM

The stock price of J. B. Chemicals & Pharmaceuticals Limited has often been near the lower end of projections, indicating that it may not be meeting investor expectations. This trend could suggest challenges ahead for the company.

Insider Transactions:

Insider Transactions for JBCHEPHARM
Insider Transactions for JBCHEPHARM


56 sell transactions of JBCHEPHARM were recorded, with market price hovering near 1709.775894165039.3 transactions to buy JBCHEPHARM shares were recorded, with market price at 1875.4333089192708.The trend of more buys compared to sells around JBCHEPHARM's current price levels may signal investor optimism. This behavior suggests that the market is expecting a favorable outcome for the stock, leading to increased buying activity.

Recommendation changes over time:

Recommendations trend for JBCHEPHARM
Recommendations trend for JBCHEPHARM


Analysts' recent buy bias toward JBCHEPHARM suggests the stock is gaining favor as a strong investment choice. This optimism could drive more investors to see JBCHEPHARM as a smart place to invest, further bolstering confidence in the company's long-term growth and potential returns.